AMZN
Amazon.com, Inc.
AMZN has the edge over CZR overall, supported by stronger modeled upside and stronger valuation.
CZR
Caesars Entertainment, Inc.
CZR trails on the overall score without a compensating advantage in the available component scores.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
CZR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Under pressure |
CZR's cash flow is currently healthy, and its revenue is stable, but its profitability and balance sheet are under pressure.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
CZR PE Valuation
CZR has no meaningful PE right now: it lost money over the past year.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
AMZN has the edge over CZR on the outlook, with more favorable earnings and revenue expectations.
CZR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| Weakening | |
| Limited | |
| Low |
Analysts expect CZR's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN has the edge over CZR on earnings quality, reporting a profit while its opponent remains loss making.
CZR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.61 | -$1.45 |
| Q2 2026 | -$2.27 | -$1.34 |
| Q1 2026 | -$2.36 | -$1.26 |
| Q4 2025 | -$2.42 | -$1.13 |
| Q3 2025 | -$1.16 | +$0.50 |
| Q2 2025 | -$0.93 | +$0.35 |
| Q1 2025 | -$1.10 | -131% |
| Q4 2024 | -$1.29 | -135% |
CZR is still losing money, but far less than before: $2.61 per share over the past year, against $13.50 at its worst in late 2020.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over CZR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN's operating margin was 14% last quarter, up 4.2 points from the same quarter a year ago, near the top of its range since 2019.
CZR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.9B | +2.5% |
| Q2 2026 | $3B | +3% |
| Q1 2026 | $2.9B | +2.7% |
| Q4 2025 | $2.9B | +4.2% |
| Q3 2025 | $2.9B | -0.2% |
| Q2 2025 | $2.9B | +2.7% |
| Q1 2025 | $2.8B | +1.9% |
| Q4 2024 | $2.8B | -0.9% |
CZR's revenue grew through 2022 and has held roughly level since: $2.9B last quarter, up 2.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -2.3 points |
| Q2 2026 | 17% | -0.9 points |
| Q1 2026 | 17% | 0 points |
| Q4 2025 | 11% | -13 points |
| Q3 2025 | 18% | -4.5 points |
| Q2 2025 | 18% | +0.2 points |
| Q1 2025 | 17% | -0.2 points |
| Q4 2024 | 24% | +4.9 points |
CZR has the edge over AMZN on profitability, with a higher operating margin.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
CZR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $95M | -23% |
| Q2 2026 | $304M | +31% |
| Q1 2026 | $36M | +$41M |
| Q4 2025 | $147M | +390% |
| Q3 2025 | $123M | +$315M |
| Q2 2025 | $232M | +86% |
| Q1 2025 | -$5M | +$179M |
| Q4 2024 | $30M | -78% |
CZR has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
CZR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -1.4% | -3M shares |
| 3 years | -5.6% | -12M shares |
| 5 years | -4.7% | -10M shares |
| Available history | +162% | +126M shares |
CZR has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | $50M |
| Q3 2025 | $79M |
| Q4 2024 | $50M |
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN has the edge over CZR on leverage, with a lower net debt burden relative to earnings.
CZR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.3x | Elevated |
| Q2 2026 | 3.3x | Elevated |
| Q1 2026 | 3.3x | Elevated |
| Q4 2025 | 3.3x | Elevated |
| Q3 2025 | 3.0x | Elevated |
| Q2 2025 | 3.0x | Elevated |
| Q1 2025 | 3.1x | Elevated |
| Q4 2024 | 3.1x | Elevated |
CZR's net debt is about 3.3 years of its operating earnings (EBITDA), up from 3.0 years a year ago.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
CZR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.5 | Neutral |
| Stochastic | 38.6 | Neutral |
CZR's weekly RSI is 55 (neutral) and its Stochastic is 39 (neutral).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
CZR PE vs Consumer Cyclical Sector
| Metric | CZR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 18x | — |
CZR has no meaningful PE right now: it lost money over the past year.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has the edge over CZR on trend strength, trading above more of its moving averages.
CZR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.2 | 0.1% above |
| 20 week MA | $29.6 | 1.1% below |
| 50 week MA | $27.3 | 7.2% above |
| 100 week MA | $27.6 | 6.3% above |
| 200 week MA | $35.7 | 18% below |
CZR's trend is mixed: it's above three of its five weekly moving averages, and 18% below its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has finished higher in five of the last six years, two of them by more than 50%. It's up 15% so far in 2026.
CZR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $59.2 | $75.8 | +28% |
| 2021 | $75.8 | $94.8 | +25% |
| 2022 | $94.8 | $43.1 | -55% |
| 2023 | $43.1 | $46.9 | +8.8% |
| 2024 | $46.9 | $33.1 | -29% |
| 2025 | $33.1 | $24.8 | -25% |
| 2026 YTD | $24.8 | $29.3 | +18% |
CZR has the edge over AMZN on returns for 2026, with the stronger performance.